Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? by Plebani, M. et al.
British Jownal o Cancer (199) 7 170-173
©) 1995 Stockton Press All rghts reserved 0007-0920/95 $12.00
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can
any combination improve the results?
M Plebanil'2, D Basso', F Navaglia', M De Paoli', A Tommasini3 and A Cipriari3
'Department ofLaboratory Medicine, University ofPadova; 2kCentre ofBiomedical Research, Castelfranco Veneto; 3Department of
Pneumologv, University ofPadova, Italy.
Summary In this study we compared the diagnostic utility of: (1) neuron-specific enolase (NSE); (2)
squamous cell carcinoma antigen (SCC); (3) carcinoembryonic antigen (CEA); and (4) cytokeratin markers
(CYFRA 21-1, TPA, TPM, TPS) in patients with small-cell lung cancer (SCLC) (21 cases) and non-small-cell
lung cancer (94 cases). For comparison we also studied 66 patients with benign lung diseases and nine with
pleural mesothelioma. NSE levels in SCLC patients were significantly higher than those in all the other groups
studied. No significant variations were found among the SCC levels in all groups. CEA levels in patients with
adenocarcinoma were significantly higher than those in all other groups studied. CYFRA 21-1 serum levels
significantly increased in patients with squamous cell carcinoma and mesothelioma, while TPA, TPS and TPM
increased in patients with lung cancer irrespective of the histological type. In patients with SCLC, high levels
of all markers except SCC were found when the disease was extensive. In patients with non-SCLC, the highest
levels of all tumour markers were usually found in those with advanced disease, although CYFRA 21-1 gave a
sensitivity of 44% when a specificity of 95% was fixed in stage I non-SCLC patients. An analysis of receiver
operating characteristic curves revealed that the highest diagnostic accuracies in distinguishing benign from
malignant lung diseases were achieved with TPM (81%), CYFRA 21-1 (72%), CEA (78%) or TPA (78%)
when using cut-off values of 46 U 1-', 3.0 g 1-g', 2.0;g l-l and 75 U l-1' respectively. When all patients were
considered, the combined evaluation of more than one marker did not significantly improve the results
obtained with TPM alone. However, taking into consideration the fact that CYFRA 21-1 is the most sensitive
index of early lung tumours and that its combined determination with TPM did not worsen the overall
sensitivity and specificity of the latter, the combined use of these two markers may be suggested as a useful
took for the diagnosis of lung tumours.
Keywords: lung cancer; CEA; CYFRA 21-1; NSE; TPA; SCC
Lung cancer, the most frequent malignant tumour in indus-
trialised countries after breast and colorectal cancer, is
classified as small-cell lung cancer (SCLC), squamous cell
carcinoma, primary adenocarcinoma and large-cell car-
cinoma. The neuroendocrine properties of SCLC give it
specific biological and clinical features. Since from a prognos-
tic and therapeutic viewpoint squamous cell carcinoma,
primary adenocarcinoma and large-cell carcinoma behave
similarly, they are all pooled into a single group named
non-small-cell lung cancer (Carney and De Leij, 1988).
In order to improve the clinical approach to lung cancer
patients, several serum tumour markers have been studied,
and in this context recent interest has been focused on the
role of serum cytokeratins (Pujol et al., 1993; Stieber et al.,
1993a,b; Ebert et al., 1994; Plebani et al., 1994; van der
Gaast et al., 1994), which make up the intermediate filament
cytoskeleton within epithelial cells, and consist of at least 19
different polypeptides, numbered 1 to 19 (Lazarides, 1980;
Moll et al., 1982).
Cytokeratins can be detected both in normal as well as in
malignant tissues of epithelial origin (Moll et al., 1982;
Broers et al., 1988), and each polypeptide seems to be typical
of certain types of epithelial differentiation (Moll et al., 1982;
Sun et al., 1983).
Tissue polypeptide antigen (TPA) detects mainly
cytokeratins 8 and 19 and, to a very small degree,
cytokeratin 18, while tissue polypeptide-specific antigen (TPS)
mainly detects cytokeratin 18 and, to a small extent,
cytokeratins 8 and 19 (Bodenmuller, 1993). TPA is recog-
nised by polyclonal antisera against cytokeratins 8, 18 and
19. To enhance the sensitivity and specificity of TPA assay, a
new assay is now available, which is based on the use of
three monoclonal antibodies directed against cytokeratins 8,
18 and 19, allowing detection of TPM antigen (Gion et al.,
1994). CYFRA 21-1 detects a fragment of cytokeratin 19
(Pujol et al., 1993). Of these markers, TPA and CYFRA 21-1
seem to be the most sensitive and specific serum markers of
lung cancer (Mizushima et al., 1991; Stieber et al., 1993a;
Ebert et al., 1994).
The neuroendocrine marker serum neuron-specific enolase
(NSE) is helpful in the diagnosis and monitoring of SCLC
(Harding et al., 1990; Jorgensen et al., 1992; Bergman et al.,
1993). Squamous cell carcinoma antigen (SCC) and car-
cinoembryonic antigen (CEA) have been extensively studied
in patients with lung cancer; however, their sensitivity and
specificity have usually been reported as low (Mizushima et
al., 1991; Jarvisalo et al., 1993; Ebert et al., 1994). Few
reports deal with a combined evaluation of various tumour
markers in lung cancer diagnosis (Mizushima et al., 1991;
Jarvisalo et al., 1993; Stieber et al., 1993a; Ebert et al., 1994).
The aims of this study were therefore to: (1) assess the
behaviour of CYFRA 21-1, TPA, TPS, TPM, NSE, SCC and
CEA in patients with SCLC and with non-small-cell lung
cancer; (2) evaluate whether their combined determination
enhances their diagnostic accuracy; and (3) assess whether
there is any correlation between tumour stage and serum
marker levels.
Materials and nethods
We studied a total of 190 subjects: 66 (42 males, 24 females,
age range 19-70) had benign lung disease (BLD, Table I);
115 (103 males, 12 females, age range 45-74) had his-
tologically confirmed lung cancer (54 squamous cell car-
cinoma, 40 adenocarcinoma and 21 small-cell lung cancer);
nine males had pleural mesothelioma (age range 50-65). The
patients with SCLC were subdivided on the basis of limited
(n = 10) or extensive (n = 11) tumour spread. Non-small-cell
lung cancer was classified as: stage I (n = 18), stage II
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1995(n = 15), stage III (n = 25) and stage IV (n = 36). After over-
night fasting, at diagnosis, a serum sample was obtained
from each subject. The sera were kept at -20C for no more
than 1 month until the biochemical determinations were
made. The following parameters were measured: CYFRA
21-1 (ELISA, Enzymun-test, Boehringer Mannheim, Italy);
TPA, TPM, NSE (Byk Gulden, Italy), TPS (Medical Systaem,
Italy), SCC (Abbott, USA) and CEA (Sorin Biomedica,
Italy).
A statistical analysis of the results was made using the
analysis of variance (ANOVA, one-way), Bonferroni's test
for pairwise comparisons (Guenther, 1964), Student's t-test
and receiver operating characteristic (ROC) curves (Weins-
tein and Fineberg, 1980).
TabMe I Benign lung diseases (BLD)
Chronic obstructive pulmonary disease 19
Sarcoidosis 14
Bronchopneumonia 10
Chronic bronchitis 7
Pulmonary fibrosis 2
Tuberculosis 4
Asthma 3
Hamartoma 2
Pleuritis 2
Cystic fibrosis I
Lofflier's syndrome I
Neurofibroma 1
Total 66
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Figure 1 shows the individual values for CYFRA 21-1 and of
CEA in the studied material; the results of the analysis of
variance and Bonferroni's test are reported in the figure
kgend.
Table H reports mean values, standard errors of the means
and findings from the statistical analysis ofTPA, TPS, TPM,
NSE and of SCC in the different patient groups. Irrespective
of the histological type, patients with lung cancer had
signifintly higher TPA, TPS and TPM than patients with
benign lung di . In contrast, the NSE levels in patients
with SCLC were signifiantly higher than those in all the
other groups studied. No signiicant variations were found
among the SCC lvels of all groups.
Table I illustrates the sensitivity of the seven serum
markers studied when a specificity of 95% was fixed; the
corresponding cut-off values are also reported.
Figure 2 reports the sensitivity values, for a fixed specificity
of 95%, of all markers in relation to tumour stage and
histological type. For non-small-cell lung cancer the TNM
classification was considered, while SCLC patients were sub-
divided on the basis of a limited or extensive disease.
Figure 3 illustrates the ROC curves of each marker in
differentiating benign from malignant lung diseases. An
analysis of the ROC curves revealed that the higher diagnos-
tic accuraces were achieved with TPM (81%, sensitivity 79%
and specificity 84%), CYFRA 21-1 (72%, sensitivity 64%
and speciiity 86%), CEA (78%, sensitivity 89% and
specificity 56%) and TPA (78%, sensitivity 82% and
specificity 71%) when using cut-off values of 46U1-',
3.0 sgl ', 2.Opgl-' and 75U1-' respectively.
Table IV reports sensitivity and specificity with the com-
bined evaluation ofCYFRA 21-1, CEA, TPA and TPM. The
highest sensitivity was obtained when three markers were
combined. This increase in sensitivity was achieved at the
cost of specificity. The best specificity, with an overall satis-
factory sensitivity, was obtained with the combination of
CYFRA 21-1 and TPM.
All the cytokeratins we studied exhibited a sinilar pattern,
being significantly higher in patients with any histologcal
lung cancer type than in patients with benign lung diseases.
As with the other cytokeratns, CYFRA 21-1 was not related
to the histological tumour type. In contrast, CEA and NSE
levels were higher in patients with adenocarcinoma and with
SCLC respectively, than in patients with other lung tumours.
Patients with squamous cell carcinoma had the highest SCC
values, although this difference was not of statistical
signifi. When, however, a specificity of 95% was fixed,
CYFRA 21-1, TPM and TPA in that order were found to be
the most sensitive index in diagnosing hmg cancer,
confirming for CYFRA 21-1 the obsrvations made by
Stieber et al. (1993a) and Ebert et al. (1994). All the other
markers had sensitivities below 35% and therefore could not
be considred singly as useful markers of different types of
lung cancer.
One of the main drawbacks of serm tumour markers is
that the highest levels are usually found when disease is-at an
advanced stage. We therefore investigated whether there is
any correlation between the markers studied and tumour
stage. Patients with SCLC were subdivided into two groups
on the basis of (1) tumour confined to one hemithorax with
or without mediastinal lymph node involvement (limited) or
(2) tumour spread beyond this limit (extensive). Non-small-
cell lung cancers were staged according to the TNM
classification. In SCLC, all markers but SCC reached high
levels in about 50% of patients with an extensive disease,
while patients with limited SCLC were discriminated from
patients with benign lung diseases in a very small percentage
of cases. Therefore, none of the tumour markers studied can
be considered an early itor of this type of hlug cancer.
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Table XI Mean values, standard errors of the means and statistical analysis of TPA, TPS, TPM, NSE
and SCC in the different patient groups
TPA (Ut-1) TPS (Ul-') TPM (Ut-') NSE (qgmlt')SCC (p.g-')
mean s.ern. Mean s.erm. Mean s.em. Mean s.em. Mean s.e n.
BLD 68 8 102 12 29 4 12 1 1.2 0.13
SQC 211* 28 193 44 152* 23 14 1 3.3 0.64
ADE 223* 43 320* 89 162* 32 14 2 5.3 3.72
SCLC 252* 83 335* 124 200* 73 67t 24 1.1 0.34
MESO 876t 491 458* 166 422t 129 17 2 1.0 0.24
ANOVA, one way
F 9.695 3.583 10.709 9.879 1.033
P< 0.001 0.01 0.001 0.001 NS
*P<0.05 as compared to BLD and tP<0.001 as compared with all the other groups. (Bonferroni's
test for pairwise comparisons). BLD, benign lung disease; SQC, squamous cell carcinoma; ADE, lung
adenocarcinoma; SCLC, small-cell lung cancer; MESO, pleural mesothelomia.
Table m Sensitivity of CYFRA 21-1, CEA, NSE, SCC, TPA,
TPM and TPS in diagnosing lung cancer when a specificity of 95%
was fixed. The corresponding cut-off values are also reported
Tumour marker Sensitivity (%) Cut-off
CYFRA 21-1 52 4sgl-'
TPM 47 100UI1'
TPA 43 150 U1- I
CEA 35 7pg 1-
TPS 25 300U 11
NSE 23 22ig 1-'
SCC 15 4 lg l-
* CYFRA 21-1 O TPA
I TPM 0 CEA
NTPS
0 NSE
9 scc
Table IV Combined evaluation of CYFRA 21-1, CEA, TPA and
TPM: sensitivity in diagnosing lung cancer (n = 124) and specificity
vs benign lung diseases (n = 66)
Markers Sensitivity (%) Specificity (%)
CYFRA 21-1 or CEA 87 49
CYFRA 21-1 or TPA 85 70
CYFRA 21-1 or TPM 79 79
CYFRA 21-1 or CEA or TPA 94 41
CYFRA 21-1 or CEA or TPM 92 42
Cut-off values were 3.0iLg 1-L', 2.0jg 1-', 75 U 1- ' and 46 U 1- I for
CYFRA 21-1, CEA, TPA and TPM respectively. Positive patients
were considered to be those having at least one marker above the
cut-off, while negative patients were considered to be those having all
markers below the cut-off.
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Fugue 2 Sensitivities of CYFRA 21-1, 1PM, TPA, CEA, TPS,
NSE and SCC in diagnosing lung cancer on the basis of tumour
stage and histology. To calculate sensitivity, a fixed specificity of
95% was considered. For non-small-cell lung cancer (a) the TNM
classifiation was considered, while patients with small-cell lung
cancer (b) were subdivided on the basis of a limited or extensive
The most sensitive indicator of patients with non-small-cell
lung cancer (stage I) was CYFRA 21-1 (44%). More
advanced stages of these tumours caused increased levels of
CYFRA 21-1 as well as of TPM, TPA and CEA, but not of
NSE and SCC.
In order to improve upon the results obtained with each
serum marker, we ascertained their sensitivity and specificity
in the diagnosis of lung cancer when evaluated together. This
was done using TPM, CYFRA 21-1, TPA and CEA. These
markers were chosen because ROC curve analysis indicated
that they had the highest diagnostic accuracies (81%, 72%,
78% and 78% for cut-off values of 46 U 1-', 3.0 iLg 1-',
False-positive results (%)
Fugue 3 Receiver operating characteristic (ROC) curves of the
seven serum markers studied in distinguishing patients with lung
cancer from patients with benign lung diseases.
75 U I` and 2.0,Ag l-' respectively). When the combination
of three markers was considered, a significant increase in
sensitivity was observed, in spite of the fact that the
specificity never exceeded 45%. Similar results were obtained
when CYFRA 21-1 was combined with CEA or TPA. The
combined evaluation of TPM and CYFRA 21-1 merits
special comment. The combination of these two markers did
not significantly modify the sensitivity and specificity ofTPM
alone. However, CYFRA 21-1 determination should be
recommended since it gave the most reliable results in iden-
tifying early non-small-cell lung tumours.
A question that might arise is which cut-off value shouldTumour nikers in lungcanmer
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be considered: the one giving a specificity of 95% or the one
giving the best combination of sensitivity and specificity and
therefore the highest accuracy? We suggest the latter in the
first instance when lung cancer is suspected and the former
when a more clear-cut distinction between benign and malig-
nant lung diseases is required. Thus, two different decision
levels can be suggested in relation to the clinical use of
tumour markers: as a first step in the diagnostic algorithm or
when a differentiation from benign lung diseases is required.
In conclusion, the use of tumour markers can be of some
help in the diagnosis of small-cell and non-small-cell lung
cancer; cytokeratins in serum are increased independently of
histological tumour type. Overall, the most sensitive and
specific indices of lung cancer are TPM and CYFRA 21-1;
their combined use is to be recommended, since the latter
was found in 44% of cases of early tumour, while the former
was found mainly in patients with advanced lung tumours.
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This study was conducted under the auspices of the Veneto Region,
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